News Bambusa, Aspen, and Tang added to IPO pipeline 2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.
News Syndax shares fall as lung fibrosis drug fails trial Syndax shares lost 17% of their value pre-market after the company said it abandoned development of axatilimab for idiopathic pulmonary fibrosis.
News Females with autoimmune disease 'less likely to be believed' Women and girls with autoimmune diseases are more likely to have their condition misdiagnosed as psychiatric or psychosomatic than males, study finds.
News Brent Saunders ejects from Bausch + Lomb once again Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.
News BMS eyes filings for idiopathic pulmonary fibrosis drug Bristol Myers Squibb has reported phase 3 results with a new drug for idiopathic pulmonary fibrosis that could open the door to regulatory filings.
News AZ makes case for hypophosphatasia drug after phase 3 miss AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.